Zontivity approved for people at high-risk of heart attack, stroke

(HealthDay)—Zontivity (vorapaxar) tablets have been approved by the U.S. and Drug Administration for people at high risk of heart attack or stroke.

The drug is the first in a new class called protease-activated receptor-1 antagonists, designed to weaken the tendency of platelets to clump and form a blood clot. But the agency said the drug increases users' risks of developing life-threatening bleeding. Zontivity's label includes a boxed warning describing this risk, the FDA said Thursday in a news release.

The drug is meant for people who have had a previous or blocked arteries in the arms or legs. It should not be used by people who have had a prior stroke, "mini-" or a prior episode of bleeding in the head, the agency warned.

The most common side effects include bleeding and bruising. Users who have these side effects should report them immediately to their doctors, the FDA advised.

Zontivity is made by Merck Sharp and Dohme Corp., whose parent Merck & Co. is based in Whitehouse Station, N.J.

More information: Visit the FDA to learn more.

add to favorites email to friend print save as pdf

Related Stories

Daily aspirin regimen not safe for everyone, FDA warns

May 06, 2014

(HealthDay)—Taking an aspirin a day can help prevent heart attack and stroke in people who have suffered such health crises in the past, but not in people who have never had heart problems, according to ...

Merck blood thinner shows mixed results: study

Mar 24, 2012

An experimental blood thinning drug made by the pharmaceutical giant Merck may reduce the risk of dying from a heart attack but also boosts the danger of internal bleeding, researchers said Saturday.

Kcentra approved to stop severe bleeding in heart patients

Apr 30, 2013

(HealthDay)—Kcentra (prothrombin complex concentrate, human) has been approved by the U.S. Food and Drug Administration to treat severe acute bleeding in adults after administration of the anti-clotting drug warfarin and ...

Northera approved for rare blood pressure condition

Feb 19, 2014

(HealthDay)—Northera (droxidopa) has been approved by the U.S. Food and Drug Administration to treat a rare, chronic condition characterized by a sudden drop in blood pressure when a person stands.

Merck: New drugs pending approval or in late tests

May 06, 2014

Merck & Co. could get an impressive six new prescription medicines approved in the U.S. this year and will soon apply for regulatory approval of two others, company executives said Tuesday during a briefing on Merck's business.

Recommended for you

Xtoro approved for swimmer's ear

12 hours ago

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

13 hours ago

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.